BioCentury | Oct 28, 2020

Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs

With $56 million in fresh funding from a crossover syndicate, newly launched Longboard will develop three neuroscience programs spun out from Arena that share familiar targets with therapies previously developed by the parent company. The...
BioCentury | Aug 8, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer Protein tyrosine phosphatase 1B (PTP-1B: PTPN1); insulin-like growth factor-1 receptor (IGF1R; CD221) Cell culture studies suggest PTP-1B could help treat IGF1R-dependent ovarian cancer....
BioCentury | Jul 26, 2012
Cover Story

Taming T cells in T1D

Separate teams at the University of California, San Francisco and Pfizer Inc. have evidence that blocking Il-7 signaling in mice can arrest the autoimmune activity behind type 1 diabetes. 1,2 Whether the findings will translate...
BioCentury | Jul 26, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes IL-7 receptor (IL-7R; CD127) Two studies in mice suggest antagonizing CD127 could help treat type 1 diabetes. In a mouse model of type...
BioCentury | Jul 9, 2012

Belviq breaks through

Arena Pharmaceuticals Inc. and partner Eisai Pharmaceuticals Co. Ltd. will have a fine line to walk as they market Belviq lorcaserin for obesity. They want to improve patient compliance, which historically has not been good...
BioCentury | May 14, 2012

Lorcaserin's niche

If FDA follows the advice of its advisory committee and approves Arena Pharmaceuticals Inc. 's lorcaserin, the biotech may be able to carve out a niche for the obesity compound despite modest efficacy and potential...
BioCentury | Mar 17, 2011
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer p97 A screening study identified P97 inhibitors that could help treat cancer. In a cell-based protein degradation assay, a lead...
BioCentury | Apr 30, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) PC4 and SFRS1 interacting protein 1 (PSIP1; p75) Studies in cell culture and in mice suggest that...
BioCentury | Jul 23, 2007
Politics, Policy & Law

Scripting Avandia suits

The mass tort litigation industry is at a crossroads. To stay in business, plaintiff's lawyers and the businesses that support them must find new prey; the optimal targets are organizations that have very deep pockets...
BioCentury | Jun 27, 2007
Clinical News

Nuclease mutations predispose mice to inflammation, cancer

...Medicine that elimination of two of the three nuclease activities of flap endonuclease 1 ( FEN1...
Items per page:
1 - 10 of 27